Literature DB >> 19616609

Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.

R Ambrus1, P Kocbek, J Kristl, R Sibanc, R Rajkó, P Szabó-Révész.   

Abstract

The rate of dissolution of drugs remains one of the most challenging aspects in formulation development of poorly water-soluble drugs. The meloxicam, a low molecular analgetic for oral administration, exhibits a slow dissolution. To improve the dissolution rate, the drug was formulated in a nanosuspension by using an emulsion-diffusion method, high-pressure homogenization or sonication. Optimization of the technological parameters (organic solvents, stabilizers, homogenization procedure and recovery of particles) allowed the formation of nanosuspensions with a particle size of 200-900 nm. SEM imaging confirmed the nanosized drug particles. Use of an SMCR method on the XRPD patterns of the nanosuspensions revealed the crystalline form of the drug and the strong interaction between meloxicam and the stabilizer. The rate of dissolution of the dried meloxicam nanosuspension was enhanced (90% in 5 min), relative to that of raw meloxicam (15% in 5 min), mainly due to the formation of nanosized particles. These results indicate the suitability of formulation procedure for preparation of nanosized poorly water-soluble drug with significantly improved in vitro dissolution rate, and thus possibly enhance fast onset of therapeutic drug effect.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19616609     DOI: 10.1016/j.ijpharm.2009.07.009

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  9 in total

1.  Dissolution studies of poorly soluble drug nanosuspensions in non-sink conditions.

Authors:  Peng Liu; Odile De Wulf; Johanna Laru; Teemu Heikkilä; Bert van Veen; Juha Kiesvaara; Jouni Hirvonen; Leena Peltonen; Timo Laaksonen
Journal:  AAPS PharmSciTech       Date:  2013-04-25       Impact factor: 3.246

2.  Developed meloxicam loaded microparticles for colon targeted delivery: Statistical optimization, physicochemical characterization, and in-vivo toxicity study.

Authors:  Syed Abdul Wasay; Syed Umer Jan; Muhammad Akhtar; Sobia Noreen; Rahman Gul
Journal:  PLoS One       Date:  2022-04-25       Impact factor: 3.752

3.  Nanocrystals for the parenteral delivery of poorly water-soluble drugs.

Authors:  Bo Sun; Yoon Yeo
Journal:  Curr Opin Solid State Mater Sci       Date:  2012-12-01       Impact factor: 11.354

4.  Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets.

Authors:  Abeer Ahmed Kassem; Fatma Ahmed Ismail; Vivian Fahim Naggar; Elsayed Aboulmagd
Journal:  AAPS PharmSciTech       Date:  2014-05-16       Impact factor: 3.246

5.  Characterization and In Vitro Skin Permeation of Meloxicam-Loaded Liposomes versus Transfersomes.

Authors:  Sureewan Duangjit; Praneet Opanasopit; Theerasak Rojanarata; Tanasait Ngawhirunpat
Journal:  J Drug Deliv       Date:  2010-11-07

6.  The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity.

Authors:  Salma M Mohyeldin; Mohammed M Mehanna; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2016-05-19

7.  Intermolecular interaction as a direct measure of water solubility advantage of meloxicam cocrystalized with carboxylic acids.

Authors:  Piotr Cysewski
Journal:  J Mol Model       Date:  2018-04-21       Impact factor: 1.810

8.  Oral Administration System Based on Meloxicam Nanocrystals: Decreased Dose Due to High Bioavailability Attenuates Risk of Gastrointestinal Side Effects.

Authors:  Noriaki Nagai; Fumihiko Ogata; Hiroko Otake; Naohito Kawasaki
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

9.  The Evaluation of Meloxicam Nanocrystals by Oral Administration with Different Particle Sizes.

Authors:  Yao Yu; Yang Tian; Hui Zhang; Qingxian Jia; Xuejun Chen; Dongzhou Kang; Yimeng Du; Shenghan Song; Aiping Zheng
Journal:  Molecules       Date:  2022-01-10       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.